Takeda Pharmaceutical (TAK) Cash from Financing Activities (2018 - 2026)

Takeda Pharmaceutical's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$1.1 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 23.82% year-over-year to -$1.1 billion; the TTM figure through Jun 2026 stood at -$3.0 billion (up 65.27% YoY), while the FY2026 annual figure was -$3.3 billion, up 33.09% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at -$1.1 billion, down from -$494.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $2.0 billion in Q2 2024, with the low at -$4.3 billion in Q4 2024.
• The 5-year median for Cash from Financing Activities is -$855.9 million (2023), against an average of -$1.1 billion.
• Peak annual rise in Cash from Financing Activities reached 582.07% in 2024, while the deepest fall reached 687.4% in 2024.
• Takeda Pharmaceutical's Cash from Financing Activities stood at -$3.1 billion in 2022, then jumped by 78.52% to -$661.4 million in 2023, then plunged by 552.41% to -$4.3 billion in 2024, then jumped by 71.02% to -$1.3 billion in 2025, then increased by 9.52% to -$1.1 billion in 2026.
• Business Quant data shows TAK's Cash from Financing Activities at -$1.1 billion in Q2 2026, -$494.1 million in Q1 2026, and -$1.3 billion in Q4 2025.